drugset / Trial / NCT00044772

Study Evaluating Venlafaxine ER in Patients With Panic Disorder

NCT00044772

Phase 3 Completed 653 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Treatment

Summary

The primary objective is to determine the efficacy, safety, and tolerability of venlafaxine extended release (ER) capsules in the treatment of outpatients with panic disorder (PD) in comparison to those of placebo.

Timeline

Start
2001-11
Primary completion
2003-04
Completion
2003-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Venlafaxine Small molecule

Indications